Cancer Research Horizons (investor - Corporate Investor)
		See something wrong or missing? Let us know
	
Offices:London
		
		
		Cancer Research Horizons is a British specialist drug discovery, development and commercialisation company
Average round investment:33.81M USD
			Average number per year:1.3
			
				
					Distribution:
					2025 (1)2024 (2)2023 (1)
					
				
			
			
				
					Portfolio companies:
					 Trogenix
 Trogenix 52 North Health
 52 North Health Infinitopes
 Infinitopes
					
				
			
			
				 Trogenix
 Trogenix 52 North Health
 52 North Health Infinitopes
 Infinitopes
					
				
					Mostly invests in:
					 United Kingdom (4)
					Manufacturing (4)
 United Kingdom (4)
					Manufacturing (4)
				
			
		
	 United Kingdom (4)
					Manufacturing (4)
 United Kingdom (4)
					Manufacturing (4)
				
				 See the entire list
				
					
	
				
			
		Showing 3 of 4 tracked investments in:
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Investors with similar profile to Cancer Research Horizons
| Name | Criteria | |
|---|---|---|
|  | What If Ventures 83% | 
 | 
|  | Unilever Ventures 83% | 
 | 
|  | ⌘ Cmd + N 83% | 
 | 
|  | HG Ventures 83% | 
 | 
|  | Mandatum Asset Management 83% | 
 | 
|  | A.Capital Ventures 83% | 
 | 
|  | Jim O’Neill 83% | 
 | 
|  | Shasta Ventures 83% | 
 | 
|  | PS Capital 83% | 
 | 
|  | InterAlpen Partners 83% | 
 | 
 Belgium
 Belgium Austria
 Austria Switzerland
 Switzerland Denmark
 Denmark Estonia
 Estonia Iceland
 Iceland Latvia
 Latvia Lithuania
 Lithuania Norway
 Norway Sweden
 Sweden France
 France Ireland
 Ireland Italy
 Italy Portugal
 Portugal Spain
 Spain